Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Niels Halama

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0344-6027; OpenAlex author ID A5063203307. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 7)
Trials
0
Grants
0
Labs led
2
Collaborators
34
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 4 papers · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 11

  1. De novo induction of tertiary lymphoid structures: an immunotherapeutic strategy in pancreatic cancer. Last author DOI 10.1038/s41392-025-02260-5↗
  2. Sex Differences in the Systemic and Local Immune Response of Pancreatic Cancer Patients. Last author DOI 10.3390/cancers15061815↗
  3. Tertiary lymphoid structures and their association to immune phenotypes and circulatory IL2 levels in pancreatic ductal adenocarcinoma. Last author DOI 10.1080/2162402x.2022.2027148↗
  4. Immune features of the peritumoral stroma in pancreatic ductal adenocarcinoma. Last author DOI 10.3389/fimmu.2022.947407↗
  5. Peripheral blood and tissue assessment highlights differential tumor-circulatory gradients of IL2 and MIF with prognostic significance in resectable pancreatic… Last author DOI 10.1080/2162402x.2021.1962135↗
  6. Langerhans islets induce anti-tumor immunity at the expense of glycemic control and predict chemotherapy response in pancreatic cancer Last author DOI 10.1101/2021.03.13.435100↗
  7. Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects. Last author DOI 10.1136/jitc-2021-002505↗
  8. Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcino… Co-author DOI 10.1158/1078-0432.ccr-21-1020↗
  9. A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pan… Co-author DOI 10.1186/s12885-017-3604-y↗
  10. Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/2162402x.2016.1240859↗
  11. Prognostic impact of a compartment-specific angiogenic marker profile in patients with pancreatic cancer. Co-author DOI 10.18632/oncotarget.2651↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christoph Springfeld · 8 shared papers, 2017–2025 · strength 1.32
  2. Azaz Ahmed · 6 shared papers, 2021–2025 · strength 1.17
  3. Dirk Jäger · 8 shared papers, 2017–2023 · strength 1.01
  4. Thilo Hackert · 6 shared papers, 2016–2023 · strength 0.79
  5. Nathalia A. Giese · 5 shared papers, 2021–2023 · strength 0.74
  6. Rosa Klotz · 5 shared papers, 2021–2023 · strength 0.74
  7. Meggy Suarez‐Carmona · 2 shared papers, 2021 · strength 0.21
  8. Nicolas Hohmann · 2 shared papers, 2021 · strength 0.21
  9. Christine E. Engeland · 2 shared papers, 2017–2021 · strength 0.15
  10. Guy Ungerechts · 2 shared papers, 2017–2021 · strength 0.15
  11. Assia L. Angelova · 2 shared papers, 2017–2021 · strength 0.15
  12. Jacek Hajda · 2 shared papers, 2017–2021 · strength 0.15
  13. Thomas Schmidt · 2 shared papers, 2014–2021 · strength 0.14
  14. Matthias M. Gaida · 1 shared paper, 2021 · strength 0.10
  15. Albrecht Stenzinger · 1 shared paper, 2017 · strength 0.05
  16. Michael Volkmar · 1 shared paper, 2016 · strength 0.04
  17. Rienk Offringa · 1 shared paper, 2016 · strength 0.04
  18. Thomas P. Hank · 1 shared paper, 2016 · strength 0.04
  19. Martin Ronald Sprick · 1 shared paper, 2016 · strength 0.04
  20. Markus Wolfgang Büchler · 1 shared paper, 2016 · strength 0.04
  21. Isabel C. Poschke · 1 shared paper, 2016 · strength 0.04
  22. Andreas Trumpp · 1 shared paper, 2016 · strength 0.04
  23. Uğur Şahin · 1 shared paper, 2016 · strength 0.04
  24. Hanno Glimm · 1 shared paper, 2016 · strength 0.04
  25. Oliver Strobel · 1 shared paper, 2016 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.